We are live on ! Find out more
PBLA

Panbela Therapeutics, Inc. Common Stock
PBLA

Delisted

PBLA was delisted on the 6th of March, 2024.

Back to rankings

10 hedge funds and large institutions have $34.5K invested in Panbela Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% less funds holding

Funds holding: 12 → 10 (-2)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

96% less capital invested

Capital invested by funds: $801K → $34.5K (-$766K)

Holders
10
Holders Change
-2
Holders Change %
-16.67%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$10.2K
2
Renaissance Technologies
Renaissance Technologies
New York
+$6.81K
3
CAN
Cetera Advisor Networks
California
+$3.41K
4
UBS Group
UBS Group
Switzerland
+$3.41K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$588K
2
CS
Clear Street
New York
-$30K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$27.3K
4
VF
Virtu Financial
New York
-$19K
5
BAMG
Brand Asset Management Group
Missouri
-$15K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$14.9K +$3.41K +1 +13%
TSS
2
Two Sigma Securities
New York
$4.85K +$10.2K +3 New
Renaissance Technologies
3
Renaissance Technologies
New York
$4K +$6.81K +2 New
Morgan Stanley
4
Morgan Stanley
New York
$2.38K -$3.41K -1 -50%
CAN
5
Cetera Advisor Networks
California
$1.66K +$3.41K +1 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.51K -$27.3K -8 -89%
OFG
7
Oxford Financial Group
Indiana
$1.47K – – –
Verition Fund Management
8
Verition Fund Management
Connecticut
$1.46K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$1K – – –
TRCT
10
Tower Research Capital (TRC)
New York
$1K – – –
Bank of America
11
Bank of America
North Carolina
$209 – – –
Northwestern Mutual Wealth Management
12
Northwestern Mutual Wealth Management
Wisconsin
$46 – – –
Wells Fargo
13
Wells Fargo
California
$15 – – –
AC
14
Armistice Capital
New York
– -$588K -91 Closed
CS
15
Clear Street
New York
– -$30K -5 Closed
VF
16
Virtu Financial
New York
– -$19K -3 Closed
BAMG
17
Brand Asset Management Group
Missouri
– -$15K -2 Closed
BSW
18
Buckingham Strategic Wealth
Missouri
– -$7K -1 Closed

PBLA Hedge Fund Activity: Q4 2022 in Review

10 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Panbela Therapeutics, Inc. Common Stock (PBLA) for Q4 2022, worth a combined $34.5K — down 96% from $801K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of PBLA and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $10.2K. The largest seller was Armistice Capital, exiting entirely with an estimated $588K sold.

  • 10 institutional investors held Panbela Therapeutics, Inc. Common Stock (PBLA) as of Q4 2022, down from 12 in Q3 2022.
  • Funds reported $34.5K of Panbela Therapeutics, Inc. Common Stock stock for Q4 2022, down 96% quarter-over-quarter.
  • 3 funds opened new Panbela Therapeutics, Inc. Common Stock positions in Q4 2022 and 5 closed out, a net change of -2 holders.
  • The largest Panbela Therapeutics, Inc. Common Stock buyer in Q4 2022 was Two Sigma Securities, an estimated $10.2K added.
  • The largest Panbela Therapeutics, Inc. Common Stock seller in Q4 2022 was Armistice Capital, an estimated $588K sold.

Based on aggregated 13F filings for Q4 2022.